Trial · NCT06456515
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
NCT06456515, Not applicable, Recruiting, The First People's Hospital of Changzhou
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC. Trials, record NCT06456515. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06456515
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
- NCT number
- NCT06456515
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- The First People's Hospital of Changzhou
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Regorafenib and Sintilimab in combination with electroacupuncture
- First posted
- 2024-06-13
- Last updated
- 2025-02-17
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | Up to 2 years | The time from randomization to death |
| Secondary | Objective response rate (ORR) | Up to 2 years | The proportion of patients that respond either partially or fully to therapy |
| Secondary | Progression-free survival (PFS) | Up to 2 years | The time from randomization until first evidence of disease progression or death |
| Secondary | Disease control rate (DCR) | Up to 2 years | Percentage of patients with advanced cancer whose therapeutic intervention has led to a complete response, partial response, or stable disease |
| Secondary | Time to progression (TTP) | Up to 2 years | The time from randomization until first evidence of disease progression |
| Secondary | Health-related quality of life (HRQoL) | Up to 2 years | Assessment of patient quality of life with respect to health status |
| Secondary | Adverse events (AE) | Up to 2 years | Use the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Overall incidence of TEAE; * Incidence of grade 3 or higher AE; * Incidence of SAEs; * Incidence of AEs leading to permanent discontinuation; * Incidence of AEs leading to medication suspension or dose adjustment. |
| Secondary | Cancer-related fatigue(CRF) | Up to 2 years | A distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning, use the Revised Piper Fatigue Scale (RPFS) |
| Secondary | Biomarker | Up to 2 years | Biomarker analysis can be categorized as "non-genetic" (e.g., associated proteins) or "genetically relevant" (e.g., associated RNA or DNA). |
| Secondary | Cmax | Up to 2 years | Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. Blood samples should be collected within 2 hours before electroacupuncture administration and 1 to 4 hours after electroacupuncture by weeks 2 and 3, and 2 hours before electroacupuncture in cycles 4-6 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06456515
GET https://conductscience.org/api/trials/v1/NCT06456515/registered